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ObituaryJean-Claude Trinchet (1951–2014)Professor Jean-Claude Trinchet passed away suddenly and
tragically December 17. As he was a shy and reclusive person,
he rarely attended international meetings and had little personal
contact with the liver establishment. Nevertheless, he was recog-
nized for his important contribution to hepatology particularly in
the ﬁeld of hepatocellular carcinoma (HCC), which he enlight-
ened on different aspects of predisposition screening methods
and treatment.
More than for the number (over 180) and quality of his publi-
cations hemust be remembered for three reasons: (1) the rigorous
methodology and scrupulous data collection that characterized
the randomized trials [1–3] or observational studies he conduct-
ed: in a word for his scientiﬁc rigor; (2) his cooperative spirit
smoothening human relationship and avoiding any mark of ego-
tism: in a word for his modesty; and (3) his personal involvement
in the clinical management of patients that provided him with
excellent clinical awareness, experience and a strong common
sense: in two words for his humanity and competence.
Jean-Claude was the principal investigator of several random-
ized studies that impacted the management of HCC patients [1–
3]. Notably, the ﬁrst important one concerning chemoemboliza-
tion was not signed by him but by an acronym: GRETCH. His wish
(that has not been granted) was to establish new rules for the
publication of multicentric trials banishing rivalry and egotism.
This trait was typical of Jean-Claude and explains why he was
considered by almost every hepatologist in France as a friend. It
is also why he succeeded in establishing national cohorts of
patients with cirrhosis. Particularly the CIRVIR cohort (started
in 2006) including more than 1600 patients with viral hepatitis
either C or B that he directed until his death and that is now start-
ing to produce a large amount of meaningful results [4,5].
The election of Jean-Claude as the leader of this cohort unique
in Europe was a consequence of the general esteem that sur-
rounded him and to his previous contribution to studies in Bondy
exploring HCC predisposing factors and other complications in
patients with cirrhosis divided according to etiology. Interesting-
ly these cohorts not only helped to reﬁne the prediction of HCC
occurrence but emphasized that predisposing SNP’s proﬁles
may differ according to the cause of the underlying liver disease,
an important step in the understanding of hepatocarcinogenesis.
The spirit of disinterested research that animated Jean-Claude
was the basis for the success of his cooperative studies. Every
hepatologist in France recognized that progress in science was
his goal, not personal promotion; his namewas also the guarantee
of a well-designed andmonitored study: an almost unique proﬁle.
One of the reasons why the studies he conducted were rele-
vant and contributive was his large clinical experience. His inter-
est in the patients was not purely academical: the profound
sorrow and sadness of his numerous patients is a testimony of
his humanity and kindness. He never forgot that the ultimate
goal of medicine, even academically, is to take care and alleviate
suffering. It is not only his patients but all the team in Bondy;
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Olivier Seror, Marianne Ziol, Jessica Zucman-Rossi and so many
others deeply miss him. I met Jean-Claude, 35 years ago; we
worked so closely and we shared difﬁculties and successes in
such an unanimous way that I realize only now that we never
had a dispute. . . a trait typical of Jean-Claude certainly (not of
me) which again emphasizes his human qualities.
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